On July 28, Stryker rose 3.5% in regular trading, trading at $352.02/share, with turnover of $140 million. The rally was driven by UBS upgrading the stock from Neutral to Buy and raising its price target from $380 to $400.

The upgrade comes just two days ahead of Stryker's scheduled Q2 earnings release on July 30 after market close. Consensus estimates project quarterly revenue of $6.58 billion, representing 10.95% year-over-year growth, with adjusted EPS expected at $3.49, up 13.67% from the prior year. According to FactSet, the stock carries an average analyst rating of Overweight with a mean price target of approximately $389.88.

Stryker has been executing on multiple growth catalysts, including the full U.S. commercial launch of its Mako RPS handheld robotic system for total knee replacement in mid-July, and the completed $835 million acquisition of Amplitude Vascular Systems adding next-generation intravascular lithotripsy technology to its peripheral vascular portfolio. The broader Health Care Equipment sector traded higher on the session, with peers Medtronic up 5.56%, Abbott Laboratories up 4.48%, Boston Scientific up 3.54%, and Intuitive Surgical up 3.89%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)